Breaking News, Collaborations & Alliances

Biocytogen, Ona Partner on ADCs Targeting Solid Tumors

Ona granted access to evaluate Biocytogen's RenMice-derived fully human antibodies against a specific tumor target.

Biocytogen Pharmaceuticals Co., Ltd., a global biotech company focusing on the discovery and development of antibody therapeutics, entered into an antibody evaluation, option, and license agreement with Ona Therapeutics, a Spanish biotech company specialized in unravelling novel biology to design biopharmaceuticals attacking advanced cancer. Ona will be granted access to evaluate Biocytogen’s RenMice-derived fully human antibodies against a specific tumor target, with an option to exclu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters